Heran Li

Dr. Heran Li

School of Pharmacy, Shenyang Pharmaceutical University

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Acta Biomaterialia
Verified
Journal Article
Closed access
KGKaijun Gou
Kaijun Gou
YWYumei Wang
Yumei Wang
XGXianmou Guo
Xianmou Guo
YWYuxin Wang
Yuxin Wang
YBYan Bian
Yan Bian
HLHeran Li
Heran Li

24 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZSZhentao Sang
Zhentao Sang
LXLu Xu
Lu Xu
RDRenyu Ding
Renyu Ding
MWMinjun Wang
Minjun Wang
XYXiaoran Yang
Xiaoran Yang
HLHeran Li
Heran Li
The oral delivery of nano-drug delivery systems (Nano-DDS) remains a challenge. Taking inspirations from viruses, here we construct core–shell mesoporous silica nanoparticles (NPs, ~80 nm) with virus-like nanospikes (VSN) to simulate viral morphology, and further modified VSN with L-alanine (CVSN) to enable chiral recognition for functional bionics. By comparing with the solid silica NPs, mesoporous silica NPs and VSN, we demonstrate the delivery advantages of CVSN on overcoming intestinal sequential barriers in both animals and human via multiple biological processes. Subsequently, we encapsulate indomethacin (IMC) into the nanopores of NPs to mimic gene package, wherein the payloads are isolated from bio-environments and exist in an amorphous form to increase their stability and solubility, while the chiral nanospikes multi-sited anchor and chiral recognize on the intestinal mucosa to enhance the penetrability and ultimately improve the oral adsorption of IMC. Encouragingly, we also prove the versatility of CVSN as oral Nano-DDS.

1 March 2021 in Acta Biomaterialia
Verified
Journal Article
Closed access
YWYumei Wang
Yumei Wang
KGKaijun Gou
Kaijun Gou
XGXianmou Guo
Xianmou Guo
JKJia Ke
Jia Ke
SLSanming Li
Sanming Li
HLHeran Li
Heran Li

14 February 2023 in ACS Nano
Verified
Journal Article
Closed access
XCXuchun Chen
Xuchun Chen
YCYing Cheng
Ying Cheng
QPQi Pan
Qi Pan
LWLan Wu
Lan Wu
XHXinyao Hao
Xinyao Hao
HLHeran Li
Heran Li

15 March 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
MXMiao Xu
Miao Xu
WXWei Xin
Wei Xin
JXJiabin Xu
Jiabin Xu
AWAnya Wang
Anya Wang
SMShuai Ma
Shuai Ma
HLHeran Li
Heran Li
The cascade reaction of lipopolysaccharides (LPS), cell-free DNA (cfDNA), and reactive oxygen species (ROS), drives the development of inflammatory bowel disease (IBD). Herein, we construct polyethylenimide (PEI)-L/D-tartaric acid (L/D-TA) complexes templated mesoporous organosilica nanoparticles (MON) (PEI-L/D-TA@MON) by mimicking biosilicification under ambient conditions within seconds. The chiral nanomedicines include four functional moieties, wherein PEI electrostatically attracts cfDNA, tetrathulfide bonds reductively react with ROS, silanol groups adsorb LPS, and L/D-TA enables chiral recognition and inflammatory localization. Following oral administration, PEI-L-TA@MON exhibiting preferential conformation stereoscopically matches with mucosa and anchors onto inflammatory intestine for lesion targeting. PEI-L-TA@MON eliminates LPS, ROS, and cfDNA, alleviating oxidative stress, inhibiting inflammatory cascade, and maintaining immune homeostasis to achieve IBD therapy. In addition, the rapid synthesis, low cost, energy-free preparation, negligible toxicity, satisfactory therapeutic effect, and facile conversion on therapeutic modes of PEI-L-TA@MON will bring changes for IBD treatment, providing research values and translational clinical prospects.

17 November 2022 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
KGKaijun Gou
Kaijun Gou
WXWei Xin
Wei Xin
JLJinying Lv
Jinying Lv
ZMZihao Ma
Zihao Ma
JYJuqin Yang
Juqin Yang
HLHeran Li
Heran Li